Federal Court Stays Class Action Against CBD Firm Green Roads To Await FDA Rulemaking
Plaintiffs against Florida-based Green Roads used certificates of analysis the company makes freely available to consumers to determine that batches of two of the company’s products contained “significantly” less cannabidiol versus labeled amounts. A Florida federal court rejected the firm’s motion to dismiss, but it is interested in seeing how FDA rulemaking develops.
You may also be interested in...
The “EWG VERIFIED” mark, and Prima’s recently earned B Corp certification, should help to bolster the company’s purpose-driven, “beyond clean” claims in consumers’ esteem. At a time of regulatory uncertainty, mounting litigation and outstanding safety questions, distinguishing one’s CBD brand from bad actors and mere opportunists increasingly is the name of the game.
Duffy MacKay, senior VP of scientific and regulatory affairs at CV Sciences, offers his predictions regarding the FDA’s likely course in regulating CBD’s use in dietary supplements – action that is sorely needed as the market continues to crowd with CBD products “with who-knows-what in them.”
Companies choosing between CBD options – namely broad- or full-spectrum hemp extracts or CBD isolate – need to appreciate the differences and potential legal implications, attorneys say.